Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Pharma-Bio Serv, Inc.

Get SEC filing alerts via email and in your feed for Pharma-Bio Serv, Inc.

PBSV

Pharma-Bio Serv, Inc.

About Pharma-Bio Serv, Inc.

Pharma-Bio Serv provides compliance consulting services to the pharmaceutical, biotech, medical device, cosmetic, and food industries. Its core offerings include regulatory compliance, validation, technology transfer, and engineering services across Puerto Rico, the U.S., Europe, and Brazil. The company leverages experienced professionals to serve major clients, focusing on quality, regulatory adherence, and market expansion within a fragmented, competitive industry.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Pharma-Bio Serv, Inc.

1
1
Pharma-Bio Serv, Inc. Pharma-Bio Serv Reports Q1 2026 Financial Results with Revenue Decline and Increased Net Income

Via official filing (AI summary) | 3 months ago | 0 comments

2
1
Pharma-Bio Serv, Inc. Pharma-Bio Serv Reports $9.0 Million Revenue for Fiscal Year Ending October 31, 2025

Via official filing (AI summary) | 4 months ago | 0 comments

3
1
Pharma-Bio Serv, Inc. Pharma-Bio Serv Reports 18.9% Revenue Decline in Q3 Fiscal 2025

Via official filing (AI summary) | 9 months ago | 0 comments

4
1
Pharma-Bio Serv, Inc. Pharma-Bio Serv Reports Q2 Fiscal 2025 Revenue Growth to $2.42 Million

Via official filing (AI summary) | 12 months ago | 0 comments

5
1
Pharma-Bio Serv, Inc. Pharma-Bio Serv Reports Revenue Increase and Improved Profitability for Quarter Ending January 31, 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Pharma-Bio Serv, Inc. Pharma-Bio Serv Reports Significant Revenue and Profit Declines in Q3 and Nine Months Ended July 31, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments